Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review

References

• CDC [webpage on the Internet]Diabetes Public Health Resource Available from: http://www.cdc.gov/diabetes/statistics/prevalence_national.htmAccessed June 17, 2016
   Google Scholar
• American Diabetes Association7 approaches to glycemic treatmentDiabetes Care201639suppl 1S52S5926696682
   PubMed Web of Science ®Google Scholar
• HirstJAFarmerAJAliRRobertsNWStevensRJQuantifying the effect of metformin treatment and dose on glycemic controlDiabetes Care201235244645422275444
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med2006355232427244317145742
   PubMed Web of Science ®Google Scholar
• American Diabetes Association5. glycemic targetsDiabetes Care201639suppl 1S39S4626696679
   PubMed Web of Science ®Google Scholar
• GarberAJAbrahamsonMJBarzilayJIAace/Ace comprehensive diabetes management algorithm 2015Endocr Pract201521443844725877012
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBKahnSEGRADE Study Research GroupRationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)Diabetes Care20133682254226123690531
   PubMed Web of Science ®Google Scholar
• ChaoECECSGLT-2 inhibitors: a new mechanism for glycemic controlClin Diabetes201432141126246672
   PubMedGoogle Scholar
• NeumillerJJEmpagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetesDrugs Context2014321226224991224
   PubMedGoogle Scholar
• CDCMedication Adherence Available from: https://www.cdc.gov/primarycare/materials/medication/docs/medication-adherence-01ccd.pdfAccessed June 17, 2016
   Google Scholar
• CramerJA systematic review of adherence with medications for diabetesDiabetes Care20042751218122415111553
   PubMed Web of Science ®Google Scholar
• LauDNauDPOral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetesDiabetes Care20042792149215315333476
   PubMed Web of Science ®Google Scholar
• BalkrishnanRRajagopalanRCamachoFTHustonSAMurrayFTAndersonRTPredictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort studyClin Ther200325112958297114693318
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med2007120871371917679131
   PubMed Web of Science ®Google Scholar
• LopezJMAnnunziataKBaileyRARupnowMFTMoriskyDEImpact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherencePatient Prefer Adherence2014868369224855344
   PubMed Web of Science ®Google Scholar
• HundalRSKrssakMDufourSMechanism by which metformin reduces glucose production in type 2 diabetesDiabetes200049122063206911118008
   PubMed Web of Science ®Google Scholar
• PowersACD’AlessioDEndocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and HypoglycemiaBruntonLLChabnerBAKnollmannBCGoodman & Gilman’s: The Pharmacological Basis of Therapeutics, 12eNew York, NYMcGraw-Hill2011
   Google Scholar
• HaringHUMerkerLSeewaldt-BeckerEEmpagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialDiabetes Care20143761650165924722494
   PubMed Web of Science ®Google Scholar
• RosenstockJSemanLJJelaskaAEfficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemiaDiabetes Obes Metab201315121154116023906374
   PubMed Web of Science ®Google Scholar
• RidderstråleMAndersenKRZellerCEMPA-REG H2H-SU Trial Investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trialLancet Diabetes Endocrinol20142969170024948511
   PubMed Web of Science ®Google Scholar
• GerichJERole of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implicationsDiabet Med201027213614220546255
   PubMed Web of Science ®Google Scholar
• HeiseTSeewaldt-BeckerEMachaSSafety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetesDiabetes Obes Metab201315761362123356556
   PubMed Web of Science ®Google Scholar
• VivianEMSodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsDrugs Context2014321226425598831
   PubMedGoogle Scholar
• Synjardy® (empagliflozin and metformin hydrochloride tablets) [package insert]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2015
   Google Scholar
• KinaanMDingHTriggleCRMetformin: an old drug for the treatment of diabetes but a new drug for the protection of the endotheliumMed Princ Pract201524540141526021280
   PubMed Web of Science ®Google Scholar
• FerranniniEBerkAHantelSLong-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetesDiabetes Care20131240154021
   Web of Science ®Google Scholar
• MerkerLHaringHUChristiansenAVEmpagliflozin as add-on to metformin in people with type 2 diabetesDiabet Med201532121555156726031566
   PubMed Web of Science ®Google Scholar
• DeFronzoRALewinAPatelSCombination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metforminDiabetes Care201538338439325583754
   PubMed Web of Science ®Google Scholar
• JorgensenCHGislasonGHAnderssonCEffects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention – a retrospective nationwide cohort studyCardiovasc Diabetol201095420843380
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) groupLancet199835291318548659742977
   PubMed Web of Science ®Google Scholar
• HongJZhangYLaiSSPREAD-DIMCAD InvestigatorsEffects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery diseaseDiabetes Care20133651304131123230096
   PubMed Web of Science ®Google Scholar
• SchrammTKGislasonGHVaagAMortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide studyEur Heart J201132151900190821471135
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• RosenstockJFerranniniEEuglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitorsDiabetes Care20153891638164226294774
   PubMed Web of Science ®Google Scholar
• PetersALBuschurEOBuseJBCohanPDinerJCHirschIBEuglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibitionDiabetes Care20153891687169326078479
   PubMed Web of Science ®Google Scholar
• Empagliflozin/metformin (synjardy) for type 2 diabetesMed Lett Drugs Ther201557148417217426670554
   PubMed Web of Science ®Google Scholar
• FDA [webpage on the Internet] Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494829.htm?source=govdelivery&utm_medium=email&utm_source=govdeliveryAccessed April 17, 2016
   Google Scholar
• RiggsMMStaabASemanLPopulation pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetesJ Clin Pharmacol201353101028103823940010
   PubMed Web of Science ®Google Scholar
• BlumerIHadarEHaddenDRDiabetes and pregnancy: an endocrine society clinical practice guidelineJ Clin Endocrinol Metab201398114227424924194617
   PubMed Web of Science ®Google Scholar
• MayMSchindlerCClinically and pharmacologically relevant interactions of antidiabetic drugsTher Adv Endocrinol Metab201672698327092232
   PubMed Web of Science ®Google Scholar